Clinical Trial

Co-administration of CART22-65s and huCART19 for B-ALL

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-01-05; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Recruiting 2023-01-25
Trial Details
NCT Number NCT05674175
Lead Sponsor Stephan Grupp MD PhD
Collaborators: University of Pennsylvania
Conditions B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
Enrollment 93 participants
Start Date 2023-01-25
Primary Completion 2028-07-01 (estimated)
Study Completion 2029-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-27